Search

Your search keyword '"A. Cauchois"' showing total 10,238 results
Start Over Author "A. Cauchois"
10,238 results on '"A. Cauchois"'

101. Eosinopenia as Predictor of Poor Outcome in Hospitalized COVID-19 Adult Patients from Waves 1 and 2 of 2020 Pandemic

Author

Cauchois, Raphael, primary, Pietri, Lea, additional, Dalmas, Jean-Baptiste, additional, Koubi, Marie, additional, Capron, Thibaut, additional, Cassir, Nadim, additional, Potere, Nicola, additional, Polidoro, Ildo, additional, Jean, Rodolphe, additional, Jarrot, Pierre-André, additional, Andre, Baptiste, additional, Veit, Veronique, additional, Carvelli, Julien, additional, Pauly, Vanessa, additional, Chanez, Pascal, additional, Papazian, Laurent, additional, and Kaplanski, Gilles, additional

Published
2022
Full Text
View/download PDF

102. Rôle de l’interniste dans la démarche diagnostique et la prise en charge des morts fœtales in utero : l’expérience d’un registre multicentrique de MFIU entre 2010 et 2019

Author

Caillault, L., primary, Garlantézec, R., additional, Le Lous, M., additional, Le Bouar, G., additional, Loget, P., additional, Cauchois, A., additional, Quelin, C., additional, Plesse, C., additional, Lescoat, A., additional, Beranger, R., additional, and Belhomme, N., additional

Published
2022
Full Text
View/download PDF

104. Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity

Author

Tellier, Edwige, primary, Widemann, Agnès, additional, Cauchois, Raphaël, additional, Faccini, Julien, additional, Lagarde, Marie, additional, Brun, Marion, additional, Robert, Philippe, additional, Robert, Stéphane, additional, Bachelier, Richard, additional, Poullin, Pascale, additional, Roose, Elien, additional, Vanhoorelbeke, Karen, additional, Coppo, Paul, additional, Dignat-George, Françoise, additional, and Kaplanski, Gilles, additional

Published
2022
Full Text
View/download PDF

105. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

Author

Evdoxia Kyriazopoulou, Thomas Huet, Giulio Cavalli, Andrea Gori, Miltiades Kyprianou, Peter Pickkers, Jesper Eugen-Olsen, Mario Clerici, Francisco Veas, Gilles Chatellier, Gilles Kaplanski, Mihai G Netea, Emanuele Pontali, Marco Gattorno, Raphael Cauchois, Emma Kooistra, Matthijs Kox, Alessandra Bandera, Hélène Beaussier, Davide Mangioni, Lorenzo Dagna, Jos W M van der Meer, Evangelos J Giamarellos-Bourboulis, Gilles Hayem, Mihai G. Netea, Jos W.M. van der Meer, Evangelos J. Giamarellos-Bourboulis, Stefano Volpi, Maria Pia Sormani, Alessio Signori, Giorgio Bozzi, Francesca Minoia, Stefano Aliberti, Giacomo Grasselli, Laura Alagna, Andrea Lombardi, Riccardo Ungaro, Carlo Agostoni, Francesco Blasi, Giorgio Costantino, Anna Ludovica Fracanzani, Nicola Montano, Flora Peyvandi, Marcello Sottocorno, Antonio Muscatello, Giovanni Filocamo, Antonios Papadopoulos, Maria Mouktaroudi, Eleni Karakike, Maria Saridaki, Theologia Gkavogianni, Konstantina Katrini, Nikolaos Vechlidis, Christina Avgoustou, Stamatios Chalvatzis, Theodoros Marantos, Christina Damoulari, Georgia Damoraki, Sofia Ktena, Maria Tsilika, Panagiotis Koufargyris, Athanasios Karageorgos, Dionysia-Irene Droggiti, Aikaterini Koliakou, Garyfallia Poulakou, Konstantinos Tsiakos, Dimitra-Melia Myrodia, Areti Gravvani, Ioannis P. Trontzas, Konstantinos Syrigos, Ioannis Kalomenidis, Eleftheria Kranidioti, Periklis Panagopoulos, Vasileios Petrakis, Simeon Metallidis, Georgia Loli, Olga Tsachouridou, George N. Dalekos, Nikolaos Gatselis, Aggelos Stefos, Sarah Georgiadou, Vassiliki Lygoura, Haralampos Milionis, Maria Kosmidou, Ilias C. Papanikolaou, Karolina Akinosoglou, Efthymia Giannitsioti, Georgios Chrysos, Panagiotis Mavroudis, Chrysanthi Sidiropoulou, Georgios Adamis, Archontoula Fragkou, Aggeliki Rapti, Zoi Alexiou, Styliani Symbardi, Aikaterini Masgala, Konstantina Kostaki, Evangelos Kostis, Michael Samarkos, Petros Bakakos, Vassiliki Tzavara, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Vasileios Kotsis, George Tsoukalas, Ioannis Bliziotis, Michael Doumas, Aikaterini Argyraki, Ilias Kainis, Massimo Fantoni, Antonella Cingolani, Andrea Angheben, Chiara Simona Cardellino, Francesco Castelli, Francesco Saverio Serino, Emanuele Nicastri, Giuseppe Ippolito, Matteo Bassetti, Carlo Selmi, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Kyriazopoulou, E., Huet, T., Cavalli, Giulio., Gori, A., Kyprianou, M., Pickkers, P., Eugen-Olsen, J., Clerici, M., Veas, F., Chatellier, G., Kaplanski, G., Netea, M. G., Pontali, E., Gattorno, M., Cauchois, R., Kooistra, E., Kox, M., Bandera, A., Beaussier, H., Mangioni, D., Dagna, L., van der Meer, J. W. M., Giamarellos-Bourboulis, E. J., Hayem, G., Volpi, S., Sormani, M. P., Signori, A., Bozzi, G., Minoia, F., Aliberti, S., Grasselli, G., Alagna, L., Lombardi, A., Ungaro, R., Agostoni, C., Blasi, F., Costantino, G., Fracanzani, A. L., Montano, N., Peyvandi, F., Sottocorno, M., Muscatello, A., Filocamo, G., Papadopoulos, A., Mouktaroudi, M., Karakike, E., Saridaki, M., Gkavogianni, T., Katrini, K., Vechlidis, N., Avgoustou, C., Chalvatzis, S., Marantos, T., Damoulari, C., Damoraki, G., Ktena, S., Tsilika, M., Koufargyris, P., Karageorgos, A., Droggiti, D. -I., Koliakou, A., Poulakou, G., Tsiakos, K., Myrodia, D. -M., Gravvani, A., Trontzas, I. P., Syrigos, K., Kalomenidis, I., Kranidioti, E., Panagopoulos, P., Petrakis, V., Metallidis, S., Loli, G., Tsachouridou, O., Dalekos, G. N., Gatselis, N., Stefos, A., Georgiadou, S., Lygoura, V., Milionis, H., Kosmidou, M., Papanikolaou, I. C., Akinosoglou, K., Giannitsioti, E., Chrysos, G., Mavroudis, P., Sidiropoulou, C., Adamis, G., Fragkou, A., Rapti, A., Alexiou, Z., Symbardi, S., Masgala, A., Kostaki, K., Kostis, E., Samarkos, M., Bakakos, P., Tzavara, V., Dimakou, K., Tzatzagou, G., Chini, M., Kotsis, V., Tsoukalas, G., Bliziotis, I., Doumas, M., Argyraki, A., Kainis, I., Fantoni, M., Cingolani, A., Angheben, A., Cardellino, C. S., Castelli, F., Serino, F. S., Nicastri, E., Ippolito, G., Bassetti, M., and Selmi, C.

Subjects
medicine.medical_specialty, Anakinra, business.industry, Secondary infection, [SDV]Life Sciences [q-bio], Immunology, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Odds ratio, Articles, Placebo, law.invention, Rheumatology, Randomized controlled trial, law, Meta-analysis, Fraction of inspired oxygen, Internal medicine, Clinical endpoint, Immunology and Allergy, Medicine, business, ComputingMilieux_MISCELLANEOUS, medicine.drug
Abstract

Contains fulltext : 237989.pdf (Publisher’s version ) (Closed access) BACKGROUND: Anakinra might improve the prognosis of patients with moderate to severe COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ support). We aimed to assess the effect of anakinra treatment on mortality in patients admitted to hospital with COVID-19. METHODS: For this systematic review and individual patient-level meta-analysis, a systematic literature search was done on Dec 28, 2020, in Medline (PubMed), Cochrane, medRxiv, bioRxiv, and the ClinicalTrials.gov databases for randomised trials, comparative studies, and observational studies of patients admitted to hospital with COVID-19, comparing administration of anakinra with standard of care, or placebo, or both. The search was repeated on Jan 22, 2021. Individual patient-level data were requested from investigators and corresponding authors of eligible studies; if individual patient-level data were not available, published data were extracted from the original reports. The primary endpoint was mortality after 28 days and the secondary endpoint was safety (eg, the risk of secondary infections). This study is registered on PROSPERO (CRD42020221491). FINDINGS: 209 articles were identified, of which 178 full-text articles fulfilled screening criteria and were assessed. Aggregate data on 1185 patients from nine studies were analysed, and individual patient-level data on 895 patients were provided from six of these studies. Eight studies were observational and one was a randomised controlled trial. Most studies used historical controls. In the individual patient-level meta-analysis, after adjusting for age, comorbidities, baseline ratio of the arterial partial oxygen pressure divided by the fraction of inspired oxygen (PaO(2)/FiO(2)), C-reactive protein (CRP) concentrations, and lymphopenia, mortality was significantly lower in patients treated with anakinra (38 [11%] of 342) than in those receiving standard of care with or without placebo (137 [25%] of 553; adjusted odds ratio [OR] 0·32 [95% CI 0·20-0·51]). The mortality benefit was similar across subgroups regardless of comorbidities (ie, diabetes), ferritin concentrations, or the baseline PaO(2)/FiO(2). In a subgroup analysis, anakinra was more effective in lowering mortality in patients with CRP concentrations higher than 100 mg/L (OR 0·28 [95% CI 0·17-0·47]). Anakinra showed a significant survival benefit when given without dexamethasone (OR 0·23 [95% CI 0·12-0·43]), but not with dexamethasone co-administration (0·72 [95% CI 0·37-1·41]). Anakinra was not associated with a significantly increased risk of secondary infections when compared with standard of care (OR 1·35 [95% CI 0·59-3·10]). INTERPRETATION: Anakinra could be a safe, anti-inflammatory treatment option to reduce the mortality risk in patients admitted to hospital with moderate to severe COVID-19 pneumonia, especially in the presence of signs of hyperinflammation such as CRP concentrations higher than 100 mg/L. FUNDING: Sobi.

Published
2021
Full Text
View/download PDF

109. 'True' Antiphospholipid Syndrome in COVID-19: Contribution of the Follow-up of Antiphospholipid Autoantibodies

Author

Robin Arcani, Raphaël Cauchois, Pierre Suchon, Samuel Weber, Rodolphe Jean, Pierre-André Jarrot, Louise Rey, Geoffroy Venton, Marie Koubi, Romain Muller, Daniel Bertin, Jean-Louis Mège, Gilles Kaplanski, Nathalie Bardin, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), and Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille)

Subjects
[SDV]Life Sciences [q-bio], Hematology, Cardiology and Cardiovascular Medicine
Abstract

International audience

Published
2022
Full Text
View/download PDF

110. A fast Dejittering approach for line scanning microscopy

Author

Duguet, Landry, Calve, Julien, Cauchois, Cyril, Weiss, Pierre, École normale supérieure de Lyon (ENS de Lyon), Simulation et Analyse de la morphogenèse in siliCo (MOSAIC), Inria Lyon, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Innopsys [Carbonne], Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Institut de Mathématiques de Toulouse UMR5219 (IMT), Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), Supported by the ANR Micro-Blind and from ANR-3IA Artificial and Natural Intelligence Toulouse Institute., ANR-21-CE48-0008,MICROBLIND,Problèmes inverses aveugles et microscopie optique(2021), and ANR-19-P3IA-0004,ANITI,Artificial and Natural Intelligence Toulouse Institute(2019)

Subjects
dynamic programming, registration, line scanning microscopy, [INFO.INFO-IM]Computer Science [cs]/Medical Imaging, convex relaxations, dejittering
Abstract

International audience; We propose two efficient optimization approaches to correct jitter effects appearing in a specific type of line scanning microscopy. In this modality, even lines suffer from a non uniform and non integer distortion with respect to odd lines, creating significant visual artifacts. The huge image size make this problem highly challenging. To handle it, we propose two techniques. One is based on dynamic programming and has a complexity linear w.r.t. the number of pixels. The second is based on a convex relaxation and can be particularly efficient for parallel architectures. Both algorithms provide globally optimal solutions. The empirical reconstruction results are of high quality.

Published
2022

112. IFN-γ Primed Wharton's Jelly Mesenchymal Stromal Cells Inhibit T Cell Proliferation By Synergistic IDO and Mitochondrial Transfer Mechanisms

Author

Pochon, Cecile, primary, Perouf, Romain, additional, Bertrand, Allan, additional, Notarantonio, Anne-Béatrice, additional, Charif, Naceur, additional, De Carvalho Bittencourt, Marcelo, additional, Fouquet, Guillemette, additional, Cauchois, Ghislaine, additional, Voisin, Charlotte, additional, Bensoussan, Danièle, additional, Emond, Patrick, additional, Sartelet, Hervé, additional, Moulin, David, additional, de Isla, Natalia, additional, d'Aveni, Maud, additional, and Rubio, Marie Thérèse, additional

Published
2022
Full Text
View/download PDF

113. “True” Antiphospholipid Syndrome in COVID-19: Contribution of the Follow-up of Antiphospholipid Autoantibodies

Author

Arcani, Robin, additional, Cauchois, Raphaël, additional, Suchon, Pierre, additional, Weber, Samuel, additional, Jean, Rodolphe, additional, Jarrot, Pierre-André, additional, Rey, Louise, additional, Venton, Geoffroy, additional, Koubi, Marie, additional, Muller, Romain, additional, Bertin, Daniel, additional, Mège, Jean-Louis, additional, Kaplanski, Gilles, additional, and Bardin, Nathalie, additional

Published
2022
Full Text
View/download PDF

119. Will face recognition revolutionise the shopping experience?

Author

Cyril Cauchois, Charlotte Pasqual, and Wael Elloumi

Subjects
Modalities, General Computer Science, Biometrics, business.industry, End user, Computer science, media_common.quotation_subject, Internet privacy, Payment, Facial recognition system, Loyalty, Feature (machine learning), Natural (music), Electrical and Electronic Engineering, business, media_common
Abstract

Today, facial recognition is a prevalent though controversial technology. It has become established as the most natural means of biometric identification, as it doesn’t require any contact or physical interaction by the end user – a feature that has become even more important during the coronavirus pandemic. Facial recognition is also one of the most adopted biometric modalities that's now being used for many and varied use-cases, such as in payments or loyalty experiences.

Published
2021
Full Text
View/download PDF

123. Factors associated with dexamethasone efficacy in COVID‐19. A retrospective investigative cohort study

Author

Robin Arcani, Raphaël Cauchois, Pierre Suchon, Rodolphe Jean, Pierre‐André Jarrot, Quentin Gomes De Pinho, Jean‐Baptiste Dalmas, Estelle Jean, Baptiste Andre, Véronique Veit, Marie Koubi, Gilles Kaplanski, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Laboratoire d'hématologie biologique [Hôpital de la Timone - Hôpital Nord - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), and Assistance Publique - Hôpitaux de Marseille (APHM)

Subjects
SARS-CoV-2, COVID-19, dexamethasone, intensive care unit, mortality, antibiotics, Anti-Bacterial Agents, COVID-19 Drug Treatment, Cohort Studies, Infectious Diseases, Virology, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Humans, Retrospective Studies
Abstract

International audience; Dexamethasone has demonstrated efficacy in reducing mortality in COVID-19. However, its practical use is badly defined. We aimed to investigate factors associated with dexamethasone efficacy in real life. Our retrospective study was conducted in two university hospitals between September and November 2020 and included all the consecutive hospitalized patients with a laboratory-confirmed SARS-CoV-2 infection assessed by RT-PCR, treated with intravenous dexamethasone (6 mg/day). Among 111 patients, 10.6% necessitated a transfer into the intensive care unit (ICU) and the 28-day mortality rate was 17.1%. The 28-day mortality rate was significantly lower in patients who demonstrated improvement at 48 h (hazard ratio [HR]: 0.17, 95% confidence interval [CI]: 0.04–0.78, p = 0.02) and 96 h (HR: 0.07, 95% CI: 0.02–0.31, p = 0.0005) after dexamethasone initiation. Apart from well-known risk factors (age, hypertension, active cancer, severe lesions on chest computed tomography [CT] scan), we found that a high viral load in nasopharyngeal swab (Cycle threshold

Published
2022
Full Text
View/download PDF

131. Automated red blood cell depletion: Results from a validation trial of the Fenwal Amicus new red blood cell depletion program

Author

Pascale Poullin, Yael Berda-Haddad, Frederick Sanderson, and Raphaël Cauchois

Subjects
Adult, Male, medicine.medical_specialty, Erythrocytes, medicine.medical_treatment, Urology, Centrifugation, 030204 cardiovascular system & hematology, Hematocrit, Hemolysis, 03 medical and health sciences, 0302 clinical medicine, Iron storage disease, Polycythemia vera, hemic and lymphatic diseases, Humans, Medicine, Prospective Studies, Adverse effect, Polycythemia Vera, Saline, Aged, Retrospective Studies, Aged, 80 and over, medicine.diagnostic_test, business.industry, Reproducibility of Results, Hematology, General Medicine, Middle Aged, medicine.disease, Red blood cell, Treatment Outcome, Apheresis, medicine.anatomical_structure, Blood Component Removal, Female, France, Hemochromatosis, business, 030215 immunology
Abstract

Purpose A new software release of the Fenwal Amicus device is now available for red blood cell (RBC) apheresis, offering RBC exchange, RBC depletion (RBCd)/RCB exchange, and RBCd procedures. The main goal of this study was to validate the new RBCd program through the accuracy of the patient's postprocedure hematocrit (HCT) (actual end HCT) to the HCT reported by the device at the end of the procedure (target end HCT). Secondary objectives were to assess the device-related significant adverse events, the patient's cellular losses, and the degree of device induced hemolysis. Methods The study was an open-label, single-center, prospective trial in adult patients eligible for RBCd. Patients were enrolled between October 2015 and June 2016. In all procedures, saline was used as replacement fluid. Blood samples were collected from the patient before and after the procedure. Device settings, adverse events, and procedure results were recorded. Results Thirty-nine patients were enrolled (34 treated for iron storage disease and 5 for polycythemia vera); only 36 were evaluable for the primary objective. The mean actual end HCT was 34.6 ± 2.79% and the mean target end HCT was 35.8 ± 2.25%. The ratio (actual end to target end HCT) was 0.97 ± 0.05 with a 95% CI demonstrating the accuracy of the target HCT. One patient experienced a vasovagal event not related to the device. Cellular losses were not clinically relevant. Conclusion The RBCd Amicus program met all RBCd efficiency and safety requirements with high accuracy of the target HCT.

Published
2020
Full Text
View/download PDF

133. IFN-γ Primed Wharton's Jelly Mesenchymal Stromal Cells Inhibit T Cell Proliferation By Synergistic IDO and Mitochondrial Transfer Mechanisms

Author

Cecile Pochon, Romain Perouf, Allan Bertrand, Anne-Béatrice Notarantonio, Naceur Charif, Marcelo De Carvalho Bittencourt, Guillemette Fouquet, Ghislaine Cauchois, Charlotte Voisin, Danièle Bensoussan, Patrick Emond, Hervé Sartelet, David Moulin, Natalia de Isla, Maud d'Aveni, and Marie Thérèse Rubio

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

134. Salivary Alpha Amylase Bronchial Measure for Early Aspiration Pneumonia Diagnosis in Patients Treated With Therapeutic Hypothermia After Out-of-hospital Cardiac Arrest

Author

Moussali, Anis, primary, Cauchois, Emi, additional, Carvelli, Julien, additional, Hraeich, Sami, additional, Bouzana, Fouad, additional, Lesaux, Audrey, additional, Boucekine, Mohamed, additional, Bichon, Amandine, additional, Gainnier, Marc, additional, Fromonot, Julien, additional, and Bourenne, Jeremy, additional

Published
2022
Full Text
View/download PDF

137. Response of a CMS HGCAL silicon-pad electromagnetic calorimeter prototype to 20–300 GeV positrons

Author

Acar, B., additional, Adamov, G., additional, Adloff, C., additional, Afanasiev, S., additional, Akchurin, N., additional, Akgün, B., additional, Khan, F.A., additional, Alhusseini, M., additional, Alison, J., additional, Alpana, A., additional, Altopp, G., additional, Alyari, M., additional, An, S., additional, Anagul, S., additional, Andreev, I., additional, Aspell, P., additional, Atakisi, I.O., additional, Bach, O., additional, Baden, A., additional, Bakas, G., additional, Bakshi, A., additional, Bannerjee, S., additional, Bargassa, P., additional, Barney, D., additional, Beaudette, F., additional, Beaujean, F., additional, Becheva, E., additional, Becker, A., additional, Behera, P., additional, Belloni, A., additional, Bergauer, T., additional, Besancon, M., additional, Bhattacharya, S., additional, Bhowmik, D., additional, Bilki, B., additional, Bloch, P., additional, Bodek, A., additional, Bonanomi, M., additional, Bonnemaison, A., additional, Bonomally, S., additional, Borg, J., additional, Bouyjou, F., additional, Bower, N., additional, Braga, D., additional, Brashear, J., additional, Brondolin, E., additional, Bryant, P., additional, Buchot Perraguin, A., additional, Bueghly, J., additional, Burkle, B., additional, Butler-Nalin, A., additional, Bychkova, O., additional, Callier, S., additional, Calvet, D., additional, Cao, X., additional, Cappati, A., additional, Caraway, B., additional, Caregari, S., additional, Cauchois, A., additional, Ceard, L., additional, Cekmecelioglu, Y.C., additional, Cerci, S., additional, Cerminara, G., additional, Chadeeva, M., additional, Charitonidis, N., additional, Chatterjee, R., additional, Chen, Y.M., additional, Chen, Z., additional, Cheng, H.J., additional, Cheng, K.y., additional, Chernichenko, S., additional, Cheung, H., additional, Chien, C.H., additional, Choudhury, S., additional, Čoko, D., additional, Collura, G., additional, Couderc, F., additional, Danilov, M., additional, Dannheim, D., additional, Daoud, W., additional, Dauncey, P., additional, David, A., additional, Davies, G., additional, Davignon, O., additional, Day, E., additional, DeBarbaro, P., additional, De Guio, F., additional, de La Taille, C., additional, De Silva, M., additional, Debbins, P., additional, Defranchis, M.M., additional, Delagnes, E., additional, Deltoro Berrio, J.M., additional, Derylo, G., additional, Dias de Almeida, P.G., additional, Diaz, D., additional, Dinaucourt, P., additional, Dittmann, J., additional, Dragicevic, M., additional, Dugad, S., additional, Dulucq, F., additional, Dumanoglu, I., additional, Dutta, V., additional, Dutta, S., additional, Dünser, M., additional, Eckdahl, J., additional, Edberg, T.K., additional, El Berni, M., additional, Elias, F., additional, Eno, S.C., additional, Ershov, Y., additional, Everaerts, P., additional, Extier, S., additional, Fahim, F., additional, Fallon, C., additional, Fedi, G., additional, Fontana Santos Alves, B.A., additional, Frahm, E., additional, Franzoni, G., additional, Freeman, J., additional, French, T., additional, Gandhi, P., additional, Ganjour, S., additional, Gao, X., additional, Garcia-Bellido, A., additional, Gastaldi, F., additional, Gecse, Z., additional, Geerebaert, Y., additional, Gerwig, H., additional, Gevin, O., additional, Ghosh, S., additional, Gilbert, A., additional, Gilbert, W., additional, Gill, K., additional, Gingu, C., additional, Gninenko, S., additional, Golunov, A., additional, Golutvin, I., additional, Gonzalez, T., additional, Gorbounov, N., additional, Gouskos, L., additional, Gray, A.B., additional, Gu, Y., additional, Guilloux, F., additional, Guler, Y., additional, Gülmez, E., additional, Guo, J., additional, Gurpinar Guler, E., additional, Hammer, M., additional, Hassanshahi, H.M., additional, Hatakeyama, K., additional, Heering, A., additional, Hegde, V., additional, Heintz, U., additional, Hinton, N., additional, Hirschauer, J., additional, Hoff, J., additional, Hou, W.-S., additional, Hou, X., additional, Hua, H., additional, Incandela, J., additional, Irshad, A., additional, Isik, C., additional, Jain, S., additional, Jheng, H.R., additional, Joshi, U., additional, Kachanov, V., additional, Kalinin, A., additional, Kalipoliti, L., additional, Kaminskiy, A., additional, Kapoor, A., additional, Kara, O., additional, Karneyeu, A., additional, Kaya, M., additional, Kaya, O., additional, Kayis Topaksu, A., additional, Khukhunaishvili, A., additional, Kiesler, J., additional, Kilpatrick, M., additional, Kim, S., additional, Koetz, K., additional, Kolberg, T., additional, Köseyan, O.K., additional, Kristić, A., additional, Krohn, M., additional, Krüger, K., additional, Kulagin, N., additional, Kulis, S., additional, Kunori, S., additional, Kuo, C.M., additional, Kuryatkov, V., additional, Kyre, S., additional, Lai, Y., additional, Lamichhane, K., additional, Landsberg, G., additional, Lange, C., additional, Langford, J., additional, Lee, M.Y., additional, Levin, A., additional, Li, A., additional, Li, B., additional, Li, J.H., additional, Li, Y.Y., additional, Liao, H., additional, Lincoln, D., additional, Linssen, L., additional, Lipton, R., additional, Liu, Y., additional, Lobanov, A., additional, Lu, R.-S., additional, Lupi, M., additional, Lysova, I., additional, Magnan, A.-M., additional, Magniette, F., additional, Mahjoub, A., additional, Maier, A.A., additional, Malakhov, A., additional, Mallios, S., additional, Mandjavize, I., additional, Mannelli, M., additional, Mans, J., additional, Marchioro, A., additional, Martelli, A., additional, Martinez, G., additional, Masterson, P., additional, Meng, B., additional, Mengke, T., additional, Mestvirishvili, A., additional, Mirza, I., additional, Moccia, S., additional, Mohanty, G.B., additional, Monti, F., additional, Morrissey, I., additional, Murthy, S., additional, Musić, J., additional, Musienko, Y., additional, Nabili, S., additional, Nagar, A., additional, Nguyen, M., additional, Nikitenko, A., additional, Noonan, D., additional, Noy, M., additional, Nurdan, K., additional, Ochando, C., additional, Odegard, B., additional, Odell, N., additional, Okawa, H., additional, Onel, Y., additional, Ortez, W., additional, Ozegović, J., additional, Ozkorucuklu, S., additional, Paganis, E., additional, Pagenkopf, D., additional, Palladino, V., additional, Pandey, S., additional, Pantaleo, F., additional, Papageorgakis, C., additional, Papakrivopoulos, I., additional, Parshook, J., additional, Pastika, N., additional, Paulini, M., additional, Paulitsch, P., additional, Peltola, T., additional, Pereira Gomes, R., additional, Perkins, H., additional, Petiot, P., additional, Pierre-Emile, T., additional, Pitters, F., additional, Popova, E., additional, Prosper, H., additional, Prvan, M., additional, Puljak, I., additional, Qu, H., additional, Quast, T., additional, Quinn, R., additional, Quinnan, M., additional, Ramos Garcia, M.T., additional, Rao, K.K., additional, Rapacz, K., additional, Raux, L., additional, Reichenbach, G., additional, Reinecke, M., additional, Revering, M., additional, Roberts, A., additional, Romanteau, T., additional, Rose, A., additional, Rovere, M., additional, Roy, A., additional, Rubinov, P., additional, Rusack, R., additional, Rusinov, V., additional, Ryjov, V., additional, Sahin, O.M., additional, Salerno, R., additional, Sanchez Rodriguez, A.M., additional, Saradhy, R., additional, Sarkar, T., additional, Sarkisla, M.A., additional, Sauvan, J.B., additional, Schmidt, I., additional, Schmitt, M., additional, Scott, E., additional, Seez, C., additional, Sefkow, F., additional, Sharma, S., additional, Shein, I., additional, Shenai, A., additional, Shukla, R., additional, Sicking, E., additional, Sieberer, P., additional, Silva, P., additional, Simsek, A.E., additional, Sirois, Y., additional, Smirnov, V., additional, Sozbilir, U., additional, Spencer, E., additional, Steen, A., additional, Strait, J., additional, Strobbe, N., additional, Su, J.W., additional, Sukhov, E., additional, Sun, L., additional, Sunar Cerci, D., additional, Syal, C., additional, Tali, B., additional, Tan, C.L., additional, Tao, J., additional, Tastan, I., additional, Tatli, T., additional, Thaus, R., additional, Tekten, S., additional, Thienpont, D., additional, Tiras, E., additional, Titov, M., additional, Tlisov, D., additional, Tok, U.G., additional, Troska, J., additional, Tsai, L.-S., additional, Tsamalaidze, Z., additional, Tsipolitis, G., additional, Tsirou, A., additional, Tyurin, N., additional, Undleeb, S., additional, Urbanski, D., additional, Ustinov, V., additional, Uzunian, A., additional, Van de Klundert, M., additional, Varela, J., additional, Velasco, M., additional, Viazlo, O., additional, Barreto Pinto, M.V., additional, Vichoudis, P., additional, Virdee, T., additional, Vizinho de Oliveira, R., additional, Voelker, J., additional, Voirin, E., additional, Vojinovic, M., additional, Wade, A., additional, Wang, C., additional, Wang, F., additional, Wang, X., additional, Wang, Z., additional, Wayne, M., additional, Webb, S.N., additional, Whitbeck, A., additional, White, D., additional, Wickwire, R., additional, Wilson, J.S., additional, Winter, D., additional, Wu, H.y., additional, Wu, L., additional, Wulansatiti Nursanto, M., additional, Yeh, C.H., additional, Yohay, R., additional, Yu, D., additional, Yu, G.B., additional, Yu, S.S., additional, Yuan, C., additional, Yumiceva, F., additional, Yusuff, I., additional, Zacharopoulou, A., additional, Zamiatin, N., additional, Zarubin, A., additional, Zenz, S., additional, Zghiche, A., additional, Zhang, H., additional, Zhang, J., additional, Zhang, Y., additional, and Zhang, Z., additional

Published
2022
Full Text
View/download PDF

139. Factors associated with dexamethasone efficacy in COVID‐19. A retrospective investigative cohort study

Author

Arcani, Robin, primary, Cauchois, Raphaël, additional, Suchon, Pierre, additional, Jean, Rodolphe, additional, Jarrot, Pierre‐André, additional, Gomes De Pinho, Quentin, additional, Dalmas, Jean‐Baptiste, additional, Jean, Estelle, additional, Andre, Baptiste, additional, Veit, Véronique, additional, Koubi, Marie, additional, and Kaplanski, Gilles, additional

Published
2022
Full Text
View/download PDF

140. Supplemental Material - Fetal Description of the Pancreatic Agenesis and Holoprosencephaly Syndrome Associated to a Specific CNOT1 Variant

Author

Cospain, Auriane, Faoucher, Marie, Cauchois, Aurélie, Carre, Wilfrid, Quelin, Chloé, and Dubourg, Christèle

Subjects
FOS: Clinical medicine, 111403 Paediatrics, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Abstract

Supplemental Material for Fetal Description of the Pancreatic Agenesis and Holoprosencephaly Syndrome Associated to a Specific CNOT1 Variant by Auriane Cospain, Marie Faoucher, Aurélie Cauchois, Wilfrid Carre, Chloé Quelin, and Christèle Dubourg in Pediatric and Developmental Pathology.

Published
2022
Full Text
View/download PDF

141. A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota

Author

Meriem Messaoudene, Reilly Pidgeon, Corentin Richard, Mayra Ponce, Khoudia Diop, Myriam Benlaifaoui, Alexis Nolin-Lapalme, Florent Cauchois, Julie Malo, Wiam Belkaid, Stephane Isnard, Yves Fradet, Lharbi Dridi, Dominique Velin, Paul Oster, Didier Raoult, François Ghiringhelli, Romain Boidot, Sandy Chevrier, David T. Kysela, Yves V. Brun, Emilia Liana Falcone, Geneviève Pilon, Florian Plaza Oñate, Oscar Gitton-Quent, Emmanuelle Le Chatelier, Sylvere Durand, Guido Kroemer, Arielle Elkrief, André Marette, Bastien Castagner, Bertrand Routy, COMBE, Isabelle, Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM)-Université de Montréal (UdeM), McGill University = Université McGill [Montréal, Canada], McGill University Health Center [Montreal] (MUHC), Centre de recherche du CHU de Québec-Université Laval (CRCHUQ), CHU de Québec–Université Laval, Université Laval [Québec] (ULaval)-Université Laval [Québec] (ULaval), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon] (ICMUB), Université de Bourgogne (UB)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Université du Québec à Montréal = University of Québec in Montréal (UQAM), Institut de Recherches Cliniques de Montréal (IRCM), Université de Montréal (UdeM), Université Laval [Québec] (ULaval), MetaGenoPolis (MGP (US 1367)), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Institut Gustave Roussy (IGR), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), and École Pratique des Hautes Études (EPHE)

Subjects
[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Bacteria, Polyphenols, Fecal Microbiota Transplantation, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Gastrointestinal Microbiome, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Mice, Oncology, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Animals, Humans, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, [SDV.MP.PAR] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology
Abstract

Several approaches to manipulate the gut microbiome for improving the activity of cancer immune-checkpoint inhibitors (ICI) are currently under evaluation. Here, we show that oral supplementation with the polyphenol-rich berry camu-camu (CC; Myrciaria dubia) in mice shifted gut microbial composition, which translated into antitumor activity and a stronger anti–PD-1 response. We identified castalagin, an ellagitannin, as the active compound in CC. Oral administration of castalagin enriched for bacteria associated with efficient immunotherapeutic responses (Ruminococcaceae and Alistipes) and improved the CD8+/FOXP3+CD4+ ratio within the tumor microenvironment. Moreover, castalagin induced metabolic changes, resulting in an increase in taurine-conjugated bile acids. Oral supplementation of castalagin following fecal microbiota transplantation from ICI-refractory patients into mice supported anti–PD-1 activity. Finally, we found that castalagin binds to Ruminococcus bromii and promoted an anticancer response. Altogether, our results identify castalagin as a polyphenol that acts as a prebiotic to circumvent anti–PD-1 resistance. Significance: The polyphenol castalagin isolated from a berry has an antitumor effect through direct interactions with commensal bacteria, thus reprogramming the tumor microenvironment. In addition, in preclinical ICI-resistant models, castalagin reestablishes the efficacy of anti–PD-1. Together, these results provide a strong biological rationale to test castalagin as part of a clinical trial. This article is highlighted in the In This Issue feature, p. 873

Published
2022
Full Text
View/download PDF

142. Production of biogas with CCS in Norway

Author

Valentin Gentile, Anastasia Isaenko, Gaelle Cauchois, Kaja Voss, and Mike Carpenter

Subjects
History, Polymers and Plastics, Business and International Management, Industrial and Manufacturing Engineering
Published
2022
Full Text
View/download PDF

143. Blue H2 and CCUS in Ukraine

Author

Gaelle Cauchois, Malavika Venugopal, Olga Gassan-zade, Hanna Kornienko, and Bendan Beck

Subjects
History, Polymers and Plastics, Business and International Management, Industrial and Manufacturing Engineering
Published
2022
Full Text
View/download PDF

147. Outcome of Critically Ill COVID-19 Patients According to the Setting of Corticosteroid Initiation—A Retrospective Observational Cohort Study

Author

Sebastian Voicu, Thomas Lacoste-Palasset, Isabelle Malissin, Shana Bekhit, Eléonore Cauchois, Sirine Dahmani, Melkir Saib, Caroline Grant, Giulia Naim, Aymen M’Rad, Adrien Pepin-Lehaleur, Jean-Michel Ekhérian, Nicolas Deye, Bruno Mégarbane, Service de Réanimation Médicale et Toxicologique [Hôpital Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Optimisation thérapeutique en Neuropsychopharmacologie (OPTeN (UMR_S_1144 / U1144)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), and Mégarbane, Bruno

Subjects
[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, corticosteroid, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, COVID-19, dexamethasone, intensive care unit, mortality, survival, Medicine (miscellaneous), [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Article, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.TOX] Life Sciences [q-bio]/Toxicology, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.TOX]Life Sciences [q-bio]/Toxicology, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Abstract

(1) Background: Corticosteroids lower 28-day all-cause mortality in critically ill COVID-19 patients. However, the outcome of COVID-19 patients referred to the intensive care unit (ICU) for respiratory deterioration despite corticosteroids initiated during hospitalization before ICU admission has been poorly investigated. Our objective was to determine survival according to corticosteroid initiation setting. (2) Methods: We conducted a cohort study including all successive critically ill COVID-19 patients treated with corticosteroids and managed in our ICU. We compared survival, whether corticosteroids were initiated before (Cb-group) or after ICU admission (Ca-group), using a propensity score matching. (3) Results: Overall, 228 patients (67 years (56–74); 168M/60F; invasive mechanical ventilation on admission, 17%) were included with 63 patients in the Cb-group and 165 patients in the Ca-group. Survival to hospital discharge was 43% versus 69%, respectively (p = 0.001). In a multivariable analysis, factors associated with death were age (odds ratio, 1.07; 95%-confidence interval, (1.04–1.11); p < 0.0001), the sequential organ failure assessment (SOFA) score on ICU admission (1.30 (1.14–1.50); p = 0.0001) and corticosteroid initiation before ICU admission (2.64 (1.30–5.43); p = 0.007). No significant differences in outcome related to corticosteroid regimen were found. (4) Conclusions: Critically ill COVID-19 patients transferred to the ICU with deterioration despite corticosteroids initiated before admission have a less favorable outcome than patients receiving corticosteroids initiated after ICU admission.

Published
2021
Full Text
View/download PDF

148. Is Endothelial Activation a Critical Event in Thrombotic Thrombocytopenic Purpura?

Author

Raphael Cauchois, Romain Muller, Marie Lagarde, Françoise Dignat-George, Edwige Tellier, Gilles Kaplanski, Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de médecine interne et immunologie clinique, AP-HM, Marseille, Centre national de référence des microangiopathies thrombotiques (CNR-MAT), Laboratoire d’Hématologie [AP-HM Hôpital de la Timone], Hôpital de la Timone [CHU - APHM] (TIMONE), and Centre national de référence des microangiopathies (CNR-MAT)

Subjects
Thrombotic thrombocytopenic purpura, [SDV]Life Sciences [q-bio], Weibel-Palade bodies, General Medicine, endothelial cells
Abstract

International audience; Thrombotic thrombocytopenic purpura (TTP) is a severe thrombotic microangiopathy. The current pathophysiologic paradigm suggests that the ADAMTS13 deficiency leads to Ultra Large-Von Willebrand Factor multimers accumulation with generation of disseminated microthrombi. Nevertheless, the role of endothelial cells in this pathology remains an issue. In this review, we discuss the various clinical, in vitro and in vivo experimental data that support the important role of the endothelium in this pathology, suggesting that ADAMTS13 deficiency may be a necessary but not sufficient condition to induce TTP. The "second hit" model suggests that in TTP, in addition to ADAMTS13 deficiency, endogenous or exogenous factors induce endothelial activation affecting mainly microvascular cells. This leads to Weibel-Palade bodies degranulation, resulting in UL-VWF accumulation in microcirculation. This endothelial activation seems to be worsened by various amplification loops, such as the complement system, nucleosomes and free heme.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results